Science Life Blog about our PNAS paper
Slight genetic changes can limit production of Alzheimer’s disease plaques
Read the Science Life blog here
Posted on October 23, 2017 by Matt Wood
Our lab is interested in molecular and cellular mechanisms of Alzheimer's disease pathogenesis. The overarching goal of our research is to gain insights from cutting-edge cell biology investigations and translate our discoveries to advance therapeutic strategies that can reduce Alzheimer's disease neuropathology and mitigate cognitive deficits in Alzheimer's disease. A primary focus of our research is the neuronal mechanisms responsible for amyloid pathology and Alzheimer’s disease-related axonal transport defects. Here, we study APP metabolism, neuronal trafficking of APP and BACE1, and axonal transport dysfunction. The second focus of our research is to characterize the biological pathways and pathogenic mechanisms regulated by the second most common late-onset Alzheimer’s disease risk factor, BIN1. Recently, we began to investigate molecular mechanisms underlying the interaction of amylin with Aβ pathology in order to explore the molecular link between type-2 diabetes and Alzheimer's disease. My group uses an integrated approach that combines hypothesis-driven mutagenesis, biochemical and pathological characterization, detailed subcellular localization, advanced live-cell imaging, superresolution microscopy, electrophysiology, and mouse behavior analysis to accomplish our goals. Cultured primary hippocampal neurons and oligodendrocytes, established cell lines, transgenic mice, and conditional knockout mice serve as experimental models in our investigation.
Congratulations to Andrew et al. Our manuscript "Reduction of the expression of the late-onset Alzheimer’s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model" published in Journal of Biological Chemistry is available online now. PDF of the paper is here: http://www.jbc.org/content/early/2019/01/28/jbc.RA118.006379.abstract
Jean-Michel Paumier - Postdoctoral Scholar
Jean-Michel joined our group in the beginning of March. He received his Ph.D. from Aix-Marseille University, AMU/CNRS Marseille, France. His thesis is entitled "Matrix metalloproteinases and Alzheimer’s disease : Study of the roles of MT1- and MT5-MMP in amyloidogenesis and neuroinflammation"
Our manuscript characterizing S-palmitoylation of BACE using KI mice has been published in the Proceedings of the National Academy of Sciences.Manuscript Link
Congratulations to Rob on his fellowship award!
Congratulations to Pierre on his award!
Congratulations to Rob for winning a best poster award at the 17th Annual Neuroscience Day held on Friday, April 7, 201 at the Lurie Medical Research Center, Northwestern University.
Congratulations to Pierre on his Alzheimer's Association Research Fellowship Award!
- our second paper on BIN1 is published on Science Matters
She has moved to Houston to lead AD drug discovery efforts.
She is now the Research Scientist, Head of Neuroscience target discovery and validation at MD Anderson Cancer Center.
We wish her the best.
Virginie Buggia-Prévot won a Best Poster Award at the The 15th Annual Neuroscience Day held on Friday, January 23, 2015 at the Lurie Medical Research Center, Northwestern University.
Our research on BACE1 is featured on page 8 of the Spring 2014 issue. Congratulations to Virginie and Celia.
Congratulations to Virginie for receiving a BrightFocus Research Fellowship Award!
Virginie's accomplishments are highlighted on the Postdoc Spotlight
Celia Fernandez gives a research presentation to Comittee on Neurobiology applicants
Celia Fernandez won a Best Poster Award, second year in a row at the The 14th Annual Neuroscience Day held on Friday, January 17, 2014 at the Lurie Medical Research Center of Northwestern University.
Posted by Kevin Jiang on January 14, 2014 in Neuroscience
New findings about a key enzyme in the development of Alzheimer’s could point to new way of targeting an important protein for therapies.
Virgine and Celia's research on BACE1 was published on January 4, 2014 in Molecular Neurodegeneration